Duplicates removed	79
Excluded during initial screening (e.g. press releases; news reports; not relevant drug/indication; preclinical study; reviews; case reports; not randomized trial)	142
Excluded during writing (e.g. reviews; duplicate data; small patient number; nonrandomized/phase I/II trials)	31
Cited efficacy/tolerability articles	4
Cited articles not efficacy/tolerability	15
Search Strategy: EMBASE, MEDLINE and PubMed from 2018 to present. Previous Adis Drug Evaluation published in 2018 was hand-searched for relevant data. Clinical trial registries/databases and websites were also searched for relevant data. Key words were niraparib, Zejula, epithelial ovarian cancer, peritoneal cancer, fallopian tube cancer, maintenance therapy. Records were limited to those in English language. Searches last updated 1 Sept 2021